MaxCyte, Inc. Increase (Decrease) in Accounts Receivable
MaxCyte, Inc. (MXCT) reported Increase (Decrease) in Accounts Receivable of $419.00 thousand for the 6-month period ending 2026-06-30, per its 10-Q filed 2026-08-13.
Financial Statements › Cash Flow › Operating Activities
us-gaap:IncreaseDecreaseInAccountsReceivable · last filed 2026-08-13
- MaxCyte, Inc. increase (decrease) in accounts receivable for the quarter ending 2026-06-30 was -$324.00K, a 236.13% decline year-over-year.
- MaxCyte, Inc. increase (decrease) in accounts receivable for the quarter ending 2026-03-31 was $743.00K, a 11.44% decline year-over-year.
- MaxCyte, Inc. increase (decrease) in accounts receivable for the quarter ending 2025-12-31 was -$4.80M, a 4031.97% decline year-over-year.
- MaxCyte, Inc. increase (decrease) in accounts receivable for the quarter ending 2025-09-30 was $2.57M.
- MaxCyte, Inc. increase (decrease) in accounts receivable for fiscal 2025 was -$1.15M.
- MaxCyte, Inc. increase (decrease) in accounts receivable for fiscal 2024 was -$1.23M.
- MaxCyte, Inc. increase (decrease) in accounts receivable for fiscal 2023 was -$5.23M, a 214.38% decline from fiscal 2022.
- MaxCyte, Inc. increase (decrease) in accounts receivable for fiscal 2022 was $4.57M, a 167.96% increase from fiscal 2021.
| Period end | Increase (Decrease) in Accounts Receivable 3 month | Increase (Decrease) in Accounts Receivable 3 month as first filed | Increase (Decrease) in Accounts Receivable 6 month | Increase (Decrease) in Accounts Receivable 6 month as first filed | Increase (Decrease) in Accounts Receivable 9 month | Increase (Decrease) in Accounts Receivable 9 month as first filed | Increase (Decrease) in Accounts Receivable 12 month | Increase (Decrease) in Accounts Receivable 12 month as first filed |
|---|---|---|---|---|---|---|---|---|
| 2026-06-30 | -$324.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2026-08-13 | $419.00K 10-Q · filed 2026-08-13 | -$4.38M derived: sum of 3 quarters · filed 2026-08-13 | -$1.81M derived: sum of 4 quarters · filed 2026-08-13 | ||||
| 2026-03-31 | $743.00K 10-Q · filed 2026-05-13 | -$4.05M derived: sum of 2 quarters · filed 2026-05-13 | -$1.48M derived: sum of 3 quarters · filed 2026-05-13 | -$1.24M derived: sum of 4 quarters · filed 2026-08-13 | ||||
| 2025-12-31 | -$4.80M derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-25 | -$2.23M derived: sum of 2 quarters · filed 2026-03-25 | -$1.99M derived: sum of 3 quarters · filed 2026-08-13 | -$1.15M 10-K · filed 2026-03-25 | ||||
| 2025-09-30 | $2.57M derived: 10-Q 9 month − 10-Q 6 month · filed 2025-11-13 | $2.81M derived: sum of 2 quarters · filed 2026-08-13 | $3.65M 10-Q · filed 2025-11-13 | $3.77M derived: sum of 4 quarters · filed 2026-08-13 | ||||
| 2025-06-30 | $238.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2026-08-13 | $1.08M 10-Q · filed 2026-08-13 | $1.20M derived: sum of 3 quarters · filed 2026-08-13 | $1.18M derived: sum of 4 quarters · filed 2026-08-13 | ||||
| 2025-03-31 | $839.00K 10-Q · filed 2026-05-13 | $961.00K derived: sum of 2 quarters · filed 2026-05-13 | $940.00K derived: sum of 3 quarters · filed 2026-05-13 | -$730.00K derived: sum of 4 quarters · filed 2026-05-13 | ||||
| 2024-12-31 | $122.00K derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-25 | $101.00K derived: sum of 2 quarters · filed 2026-03-25 | -$1.57M derived: sum of 3 quarters · filed 2026-03-25 | -$1.23M 10-K · filed 2026-03-25 | ||||
| 2024-09-30 | -$21.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2025-11-13 | -$1.69M derived: sum of 2 quarters · filed 2025-11-13 | -$1.35M 10-Q · filed 2025-11-13 | -$3.00M derived: sum of 4 quarters · filed 2025-11-13 | ||||
| 2024-06-30 | -$1.67M derived: 10-Q 6 month − 10-Q 3 month · filed 2025-08-06 | -$1.33M 10-Q · filed 2025-08-06 | -$2.98M derived: sum of 3 quarters · filed 2025-08-06 | -$2.56M derived: sum of 4 quarters · filed 2025-08-06 | ||||
| 2024-03-31 | $343.00K 10-Q · filed 2025-05-08 | -$1.31M derived: sum of 2 quarters · filed 2025-05-08 | -$893.00K derived: sum of 3 quarters · filed 2025-05-08 | -$1.48M derived: sum of 4 quarters · filed 2025-05-08 | ||||
| 2023-12-31 | -$1.66M derived: 10-K 12 month − 10-Q 9 month · filed 2025-03-11 | -$1.24M derived: sum of 2 quarters · filed 2025-03-11 | -$1.83M derived: sum of 3 quarters · filed 2025-03-11 | -$5.23M 10-K · filed 2025-03-11 | ||||
| 2023-09-30 | $419.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2024-11-06 | -$172.00K derived: sum of 2 quarters · filed 2024-11-06 | -$3.57M 10-Q · filed 2024-11-06 | -$3.27M 10-Q · filed 2023-11-08 | $441.20K derived: sum of 4 quarters · filed 2024-11-06 | |||
| 2023-06-30 | -$591.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2024-08-06 | -$3.99M 10-Q · filed 2024-08-06 | -$3.82M 10-Q · filed 2023-08-09 | $22.20K derived: sum of 3 quarters · filed 2024-08-06 | $23.10K derived: sum of 4 quarters · filed 2024-08-06 | |||
| 2023-03-31 | -$3.40M 10-Q · filed 2024-05-07 | -$3.36M 10-Q · filed 2023-05-10 | $613.20K derived: sum of 2 quarters · filed 2024-05-07 | $614.10K derived: sum of 3 quarters · filed 2024-05-07 | -$580.80K derived: sum of 4 quarters · filed 2024-05-07 | |||
| 2022-12-31 | $4.01M derived: 10-K 12 month − 10-Q 9 month · filed 2024-03-12 | $4.01M derived: sum of 2 quarters · filed 2024-03-12 | $2.82M derived: sum of 3 quarters · filed 2024-03-12 | $4.57M 10-K · filed 2024-03-12 | $4.78M 10-K · filed 2023-03-15 | |||
| 2022-09-30 | $900.00 derived: 10-Q 9 month − 10-Q 6 month · filed 2023-11-08 | -$1.19M derived: sum of 2 quarters · filed 2023-11-08 | $556.80K 10-Q · filed 2023-11-08 | $1.48M derived: sum of 4 quarters · filed 2023-11-08 | ||||
| 2022-06-30 | -$1.19M derived: 10-Q 6 month − 10-Q 3 month · filed 2023-08-09 | $555.90K 10-Q · filed 2023-08-09 | $1.47M derived: sum of 3 quarters · filed 2023-08-09 | $1.71M derived: sum of 4 quarters · filed 2023-08-09 | ||||
| 2022-03-31 | $1.75M 10-Q · filed 2023-05-10 | $2.67M derived: sum of 2 quarters · filed 2023-05-10 | $2.91M derived: sum of 3 quarters · filed 2023-05-10 | $4.33M derived: sum of 4 quarters · filed 2023-05-10 | ||||
| 2021-12-31 | $918.90K derived: 10-K 12 month − 10-Q 9 month · filed 2023-03-15 | $1.16M derived: sum of 2 quarters · filed 2023-03-15 | $2.58M derived: sum of 3 quarters · filed 2023-03-15 | $1.71M 10-K · filed 2023-03-15 | ||||
| 2021-09-30 | $238.90K derived: 10-Q 9 month − 10-Q 6 month · filed 2022-11-09 | $1.66M derived: sum of 2 quarters · filed 2022-11-09 | $786.20K 10-Q · filed 2022-11-09 | $2.22M derived: sum of 4 quarters · filed 2022-11-09 | ||||
| 2021-06-30 | $1.42M derived: 10-Q 6 month − 10-Q 3 month · filed 2022-08-10 | $547.30K 10-Q · filed 2022-08-10 | $1.98M derived: sum of 3 quarters · filed 2022-08-10 | $1.97M derived: sum of 4 quarters · filed 2022-08-10 | ||||
| 2021-03-31 | -$877.60K 10-Q · filed 2022-05-09 | $553.40K derived: sum of 2 quarters · filed 2022-05-09 | $547.00K derived: sum of 3 quarters · filed 2022-05-09 | |||||
| 2020-12-31 | $1.43M derived: 10-K 12 month − 10-Q 9 month · filed 2022-03-22 | $1.42M derived: sum of 2 quarters · filed 2022-03-22 | $1.81M 10-K · filed 2022-03-22 | |||||
| 2020-09-30 | -$6.40K derived: 10-Q 9 month − 10-Q 6 month · filed 2021-11-10 | $379.20K 10-Q · filed 2021-11-10 | ||||||
| 2020-06-30 | $385.60K 10-Q · filed 2021-09-13 | |||||||
| 2019-12-31 | -$1.59M 10-K · filed 2022-03-22 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| bioAffinity Technologies, Inc. (BIAF) | United States | $0.063B | |
| OneMedNet Corp (ONMD) | $0.042B | ||
| iSpecimen Inc. (ISPC) | United States | $0.003B | |
| FOXO TECHNOLOGIES INC. (FOXO) | United States | $0.000B | -277.71 |
| NRC HEALTH (NRC) | United States | $0.450B | 42.50 |
| OmniAb, Inc. (OABI) | United States | $0.698B | -8.05 |
| Absci Corp (ABSI) | United States | $1.775B | -14.92 |
| CHARLES RIVER LABORATORIES INTERNATIONAL, INC. (CRL) | United States | $14.060B | -43.97 |
| Medpace Holdings, Inc. (MEDP) | United States | $17.316B | 30.09 |
| INCYTE CORP (INCY) | United States | $24.855B | 13.14 |